Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial

Background Combining the antibiotic azithromycin and hydroxychloroquine induces airway immunomodulatory effects, with the latter also having in vitro antiviral properties. This may improve outcomes in patients hospitalised for coronavirus disease 2019 (COVID-19). Methods Placebo-controlled double-blind randomised multicentre trial. Patients aged ≥18 years, admitted to hospital for ≤48 h (not intensive care) with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription PCR test were recruited. The intervention was 500 mg daily azithromycin for 3 days followed by 250 mg daily azithromycin for 12 days combined with 200 mg twice-daily hydroxychloroquine for all 15 days. The control group received placebo/placebo. The primary outcome was days alive and discharged from hospital within 14 days (DAOH14). Results After randomisation of 117 patients, at the first planned interim analysis, the data and safety monitoring board recommended stopping enrolment due to futility, based on pre-specified criteria. Consequently, the trial was terminated on 1 February 2021. 61 patients received the combined intervention and 56 patients received placebo. In the intervention group, patients had a median (interquartile range) 9.0 (3–11) DAOH14 versus 9.0 (7–10) DAOH14 in the placebo group (p=0.90). The primary safety outcome, death from all causes on day 30, occurred for one patient in the intervention group versus two patients receiving placebo (p=0.52), and readmittance or death within 30 days occurred for nine patients in the intervention group versus six patients receiving placebo (p=0.57). Conclusions The combination of azithromycin and hydroxychloroquine did not improve survival or length of hospitalisation in patients with COVID-19. There are no beneficial or harmful effects from the combined intervention of hydroxychloroquine and azithromycin for hospitalised patients with confirmed coronavirus disease 2019 (COVID-19) https://bit.ly/3c0s6XG

[1]  J. Fajar,et al.  Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis , 2021, F1000Research.

[2]  Samuel M. Brown,et al.  A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.

[3]  X. Bobbia,et al.  Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial. , 2020, JAMA.

[4]  Samuel M. Brown,et al.  Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[5]  T. Biering-Sørensen,et al.  Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan , 2020, Trials.

[6]  D. Goletti,et al.  Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review , 2020, Drugs.

[7]  P. Zimetbaum,et al.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[8]  J. Fantini,et al.  Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. , 2020, International journal of antimicrobial agents.

[9]  Á. Avezum,et al.  Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.

[10]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.

[11]  T. Biering-Sørensen,et al.  Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[12]  D. Roden,et al.  Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. , 2020, Circulation.

[13]  Q. Bassat,et al.  Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.

[14]  W. Boersma,et al.  Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. , 2019, The Lancet. Respiratory medicine.

[15]  J. Vestbo,et al.  Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. , 2019, The Lancet. Respiratory medicine.

[16]  M. Suga,et al.  Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. , 2018, International journal of antimicrobial agents.

[17]  J. Walters,et al.  Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. , 2003, The Cochrane database of systematic reviews.